HIGHLIGHTS
- who: Luca Ielasi and collaborators from the Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy have published the research work: Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma, in the Journal: Cancers 2023, 1523 of 31/Oct/2022
- what: The aim of this study is to verify whether the different metastatic sites have clinical relevance in a large multicentric population of patients treated with sorafenib for metastatic HCC . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.